EYESERYL® is a tetrapeptide with anti-oedema properties that shows a proven efficacy in reducing puffy eyebags.

INCI
WATER (AQUA), ACETYL TETRAPEPTIDE-5

PRESENTATION
EYESERYL® SOLUTION containing 0.1% active peptide

USE LEVEL
1 - 10%

FUNCTION
ANTI-EYEBAG ELASTICITY

Cosmetic benefits
- Fast anti-eyebag action: the draining effect of EYESERYL® achieves a reduction of puffy eyebags in only 15 days
- EYESERYL® fights oedema-forming mechanisms such as liquid retention
- EYESERYL® also enhances skin elasticity, skin smoothness and shows a decongesting effect

Efficacy tests

ANTI-PUFFINESS ACTIVITY
IN VIVO TEST ON VOLUNTEERS - QUALITATIVE

EYESERYL® has been tested in vivo on a group of 20 female volunteers. A cream containing 10% EYESERYL® SOLUTION was applied twice a day during 60 days. Pictures were taken at 0, 15, 30, 45 and 60 days. Puffiness under the eyes was greatly reduced, and 70% of the volunteers had improved in only 15 days.

At the end of the test, 95% of the volunteers had improved.
IN VIVO TEST ON VOLUNTEERS - QUANTITATIVE

The test was performed on 17 people, aged 34 to 54. A Cream containing 1% EYESERYL® SOLUTION was applied twice daily during 28 days.

Eyebag volume was measured using a technique called Fringe Projection where 3D images of the study areas are obtained with a FaceScanner and processed with the software Optocat (Breuckman, Germany – EoTech, France). High resolution photographs of the dark circles were taken under polarised light and chromometry studies were performed.

ANTI-PUFFINESS ACTIVITY

Evolution of eyebag volume after 15 days

Placebo    Eyseryl Cream

Percentage (%)

Eyebags were significantly reduced by almost 3% in only 15 days!

After 14 days, 63% volunteers had reduced their eyebags

After 28 days, 70% volunteers had reduced their eyebags

ANTI-DARK CIRCLE ACTIVITY

Evolution of dark circles after 15 days

The ITA® parameter indicates skin colour category as follows:

Brown < 10° <tanned < 28° <normal < 41° <light < 55° <very light

ITA significantly increased (+3%) showing a slight lightening effect.

L* is luminance which represents relative brightness from total darkness (L* = 0) to absolute white (L* = 100)

a* is red/green colour axis and b* is yellow-blue colour axis

VASCULAR PERMEABILITY INHIBITION

One of the main causes of formation of eyebags is water accumulation due to increased capillary permeability. The in vitro vascular permeability test provides an efficient system for evaluating the effects of EYESERYL® on endothelial cell permeability.

Results show that EYESERYL® is able to inhibit vascular permeability in a dose-dependent manner, reaching a 50% inhibition respect to controls with 1mg/mL (0.1%) EYESERYL®. This activity in vitro would be translated in vivo in a decrease of water accumulation in eyebags, since EYESERYL® avoids water leakage from blood vessels.

GLYCATION INHIBITION

Collagen cross-linking, which is a reaction produced after glycation and produces damages on the extracellular matrix, is one of the main causes of the formation of eyebags. This test was carried out to evaluate the ability of EYESERYL® to inhibit glycation.

The incubation of Superoxide Dismutase (SOD) with sugars gives rise to glycation, which inactivates the enzyme. In this study, the inactivation of SOD by its reaction with fructose is used as a model of glycation. The effect of EYESERYL® as an inhibitor of glycation is evaluated.

The results showed that there is an increase in the SOD activity, which means that EYESERYL® inhibits its glycation, and therefore prevents the formation of eyebags.

EYESERYL® is a registered trademark of Lipotec S.A.